Many patients with meningioma require long-term follow-up, and since Ki-67 expression is a valuable prognostic marker, a tailored follow-up strategy is necessary to balance patient well-being with effective disease management, as traditional imaging methods struggle to assess tumor proliferation accurately (9). This evidence concerns the gene MKI67 and meningioma.